<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675246</url>
  </required_header>
  <id_info>
    <org_study_id>CORTICOID001</org_study_id>
    <nct_id>NCT00675246</nct_id>
  </id_info>
  <brief_title>Antenatal Corticoid Therapy for Late Preterm Babies</brief_title>
  <acronym>ACTLPT</acronym>
  <official_title>Antenatal Corticoid Therapy for Fetal Lung Maturation in Late Preterm Pregnancies: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effectiveness of antenatal corticosteroid therapy in late
      preterm babies. The investigators hypothesis is corticoid accelerates fetal lung maturation
      even after 34 weeks and reduces risk of respiratory distress syndrome and other neonatal
      morbidities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Late preterm babies have important morbidity when compared with term babies, with oxygen
      requirement and more days of hospitalization. If antenatal corticosteroid therapy is
      necessary for fetal lung maturation after 34 weeks, it remains to be established. The
      systematic review with metanalysis in Cochrane Library includes a small number of late
      preterm babies and no conclusion about effectiveness of corticoid therapy in this setting
      could be drawn. Our hypothesis is that antenatal corticosteroid therapy is effective to
      prevent respiratory disease and morbidity in late preterm babies and this study will be
      carried out to evaluate this question.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neonatal respiratory distress</measure>
    <time_frame>neonatal period (28 days of life)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>during of neonatal hospitalization</measure>
    <time_frame>neonatal period (28 days of life)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal oxygen requirement</measure>
    <time_frame>neonatal period (28 days of life)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal sepsis</measure>
    <time_frame>neonatal period (28 days of life)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal death</measure>
    <time_frame>neonatal period (28 days of life)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Hyaline Membrane Disease</condition>
  <condition>Transient Tachypnea</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antenatal corticoid therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>CELESTONE SOLUSPAN (MANTECORP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancy between 34 and 36 weeks

          -  Confirmed gestational age (LMP, USG)

          -  Alive fetus

          -  Imminent risk of preterm delivery

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Major fetal malformations

          -  Comproved fetal lung maturity

          -  Maternal or fetal indication for immediate interruption of pregnancy

          -  Maternal hemorrhagic syndromes (placenta previa, abruptio placenta)

          -  Chorioamnionitis

          -  Chronic use of corticosteroids

          -  Previous use of corticosteroids for fetal lung maturation in the current pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melania Amorim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Materno Infantil Prof. Fernando Figueira</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Materno Infantil Prof. Fernando Figueira</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2008</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ana Maria Feitosa Porto</name_title>
    <organization>Instituto Materno Infantil Prof. Fernando Figueira</organization>
  </responsible_party>
  <keyword>corticoid therapy</keyword>
  <keyword>fetal lung maturation</keyword>
  <keyword>late preterm</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>neonatal death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachypnea</mesh_term>
    <mesh_term>Hyaline Membrane Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Betamethasone acetate phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

